Prasco to market authorized generic of NeoProfen Injection
Privately held US generic drugmaker Prasco Laboratories has entered into a distribution and supply agreement with Recordati Rare Diseases, a unit of Italian pharma firm Recordati (RC: MI), for the rights to distribute the authorized generic version of NeoProfen (ibuprofen lysine) Injection.
This product is the latest to be added to the authorized generic pipeline offered by Prasco. Additional information regarding the NeoProfen authorized copy will be forthcoming, the US company said.
"We are pleased to welcome Recordati Rare Diseases as Prasco's newest authorized generic partner. Prasco is committed to expanding patient access to brand quality pharmaceutical products through our Authorized Generics line," stated Prasco chief executive Chris Arington.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze